LEXINGTON, Massachusetts, July 16 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the
global specialty biopharmaceutical company, announces it has received Fast Track
designation from the U.S. Food and Drug Administration (FDA) for velaglucerase
alfa, its enzyme replacement therapy in development for the treatment of Type I
Gaucher disease. Shire is working with the FDA to determine subsequent steps and
timing for the filing of its NDA.

TORONTO, July 13 --

Toronto-based franchise consulting network MatchPoint is pleased to announce
its expansion into the United Kingdom.

The company officially entered the UK last year but has spent that time
expanding its network to over 20 consultants and over 30 franchise clients. To
celebrate this impressive growth, MatchPoint president Nigel Mayne and other
company officials recently ventured overseas for a week of intensive training
sessions and seminars with UK franchisees and franchisors including ActionCOACH,
Sandler Training, Antal International, Tutor Doctor and WSI.

LONDON, July 15 --

- Open call for entries for Israel round of the global innovation competition
culminating in awards on September 15 2009

Medtronic today announced that its Reclaim(R) Deep Brain Stimulation (DBS) Therapy has received CE (Conformite Europeene) Mark approval for the treatment of chronic, severe treatment-resistant obsessive-compulsive disorder (OCD).

This is the first time that a deep brain stimulation therapy has gained approval in Europe for the treatment of a psychiatric disorder.

HOUSTON, July 15 --

Endeavour International Corporation (NYSE-Amex: END) (LSE: ENDV) will host a
conference call to discuss its 2009 second quarter financial and operating
results on Tuesday, August 4, 2009 at 9 a.m. Central Daylight Time, 3 p.m.
British Summer Time.

To participate and ask questions during the conference call, dial the local
country telephone number and the confirmation code 2438753. The toll-free
numbers are +1-888-599-8658 in the United States and 0-800-051-7166 in the
United Kingdom. Other international callers should dial +1-913-312-1269 (tolls
apply). To listen only to the live audio web cast, access Endeavour’s home
page at http://www.endeavourcorp.com.

DITTON PARK, England, July 15 --

- Work Related Stress Costs EU Businesses EUR20 Billion a Year(1)

CA (NASDAQ: CA), the world’s leading independent provider of IT
management software, has released the results of a new independent survey: The
2009 ’CA Web Stress Index’.

NEW YORK, July 13 --

- Report notes that the Business Transaction Management vendor is
’building on the company’s success in an increasing number of
markets’

DUBLIN and WASHINGTON, July 16 --

- Instant Mobilizer also noted by Entrepreneur magazine as reason dotMobi is
one of the world’s 100 brilliant companies

dotMobi, the company behind .mobi - the only ICANN-approved naming convention
for helping consumers find mobile Web sites - today announced a series of
user-friendly improvements to its internationally recognized Instant Mobilizer
service.

REDMOND, Washington, July 13 --

- Industry technology leaders help banks evolve to a standard information
technology infrastructure for greater organizational flexibility,
interoperability, cost control and risk mitigation in today’s turbulent
marketplace.

Microsoft Corp. today announced that the Banking Industry Architecture Network
(BIAN) alliance has published the first major banking industry information
technology (IT) services standards to its members and the banking community at
large.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

VANCOUVER, Canada, July 13 -- Sirius Genomics, a developer of pharmacogenomic
diagnostics, announced today that it has signed a collaborative agreement with
the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations
in severe sepsis patients. The agreement focuses on the continued development of
Sirius’ pharmacogenomic diagnostic intended to assess responsiveness to
recombinant human activated Protein C (sold by Eli Lilly and Company under the
trademark Xigris (R)) in patients with severe sepsis at high risk of death.